Huayuan Zhao

Huayuan Zhao

Auto-generated profile, based on publicly available information

Huayuan Zhao

Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 March 2025 in Cancer Research
Verified
Journal Article
Open access
YYYanchao Yu
Yanchao Yu
XGXincheng Gao
Xincheng Gao
HZHuayuan Zhao
Huayuan Zhao
JSJiayin Sun
Jiayin Sun
MWMiao Wang
Miao Wang
XXXingyuan Xiao
Xingyuan Xiao
Mutations of the FGFR family members are frequently observed in metastatic bladder cancer. The development of erdafitinib, a pan-FGFR inhibitor, provided a significant therapeutic advance in bladder cancer, but resistance still limits its efficacy. In this study, we performed an unbiased whole-genome CRISPR-Cas9 synthetic lethal screen on FGFR-mutant bladder cancer cell lines treated with erdafitinib and identified spermidine synthase (SRM) as a critical contributor to erdafitinib resistance. Moreover, hypusinated eIF5A, catalyzed by SRM-mediated spermidine production, facilitated the efficient translation of HMGA2, which in turn promoted the expression of EGFR. Notably, pharmacologic inhibition of SRM enhanced the efficacy of erdafitinib both in vitro and in vivo. Together, these results offer evidence that targeting SRM could attenuate the translation of HMGA2 and subsequently reduce EGFR transcription, thus enhancing the sensitivity of FGFR-mutant bladder cancer cells to erdafitinib treatment. Significance: Combined inhibition of polyamine metabolism and FGFR is a promising therapeutic strategy to overcome erdafitinib resistance and improve treatment for patients with FGFR-mutant bladder cancer.

16 June 2025
Verified
Other
Open access
YYYanchao Yu
Yanchao Yu
XGXincheng Gao
Xincheng Gao
HZHuayuan Zhao
Huayuan Zhao
JSJiayin Sun
Jiayin Sun
MWMiao Wang
Miao Wang
XXXingyuan Xiao
Xingyuan Xiao
Figure. S2 shows that SRM loss enhances erdafitinib efficacy in bladder cancer.

16 June 2025
Verified
Other
Open access
YYYanchao Yu
Yanchao Yu
XGXincheng Gao
Xincheng Gao
HZHuayuan Zhao
Huayuan Zhao
JSJiayin Sun
Jiayin Sun
MWMiao Wang
Miao Wang
XXXingyuan Xiao
Xingyuan Xiao
Mutations of the FGFR family members are frequently observed in metastatic bladder cancer. The development of erdafitinib, a pan-FGFR inhibitor, provided a significant therapeutic advance in bladder cancer, but resistance still limits its efficacy. In this study, we performed an unbiased whole-genome CRISPR-Cas9 synthetic lethal screen on FGFR-mutant bladder cancer cell lines treated with erdafitinib and identified spermidine synthase (SRM) as a critical contributor to erdafitinib resistance. Moreover, hypusinated eIF5A, catalyzed by SRM-mediated spermidine production, facilitated the efficient translation of HMGA2, which in turn promoted the expression of EGFR. Notably, pharmacologic inhibition of SRM enhanced the efficacy of erdafitinib both in vitro and in vivo. Together, these results offer evidence that targeting SRM could attenuate the translation of HMGA2 and subsequently reduce EGFR transcription, thus enhancing the sensitivity of FGFR-mutant bladder cancer cells to erdafitinib treatment.Significance:Combined inhibition of polyamine metabolism and FGFR is a promising therapeutic strategy to overcome erdafitinib resistance and improve treatment for patients with FGFR-mutant bladder cancer.

16 June 2025
Verified
Other
Open access
YYYanchao Yu
Yanchao Yu
XGXincheng Gao
Xincheng Gao
HZHuayuan Zhao
Huayuan Zhao
JSJiayin Sun
Jiayin Sun
MWMiao Wang
Miao Wang
XXXingyuan Xiao
Xingyuan Xiao
Identification of synthetic lethal genes for erdafitinib in MGH-U3 and SW780 cells using Venn analysis.